All News

2018

October

Media Release / Oct 08, 2018

Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients

Read More
Media Release / Oct 04, 2018

Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges

Read More
Media Release / Oct 03, 2018

Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals

Read More
Surface of an engineered T cell
Story / Oct 01, 2018

Researchers boost understanding of T-cell therapy in blood cancer

Novartis investigators find genetic explanations for why some young patients relapse.

Read More

September

Media Release / Sep 24, 2018

Novartis announces five grant recipients of eXcellence in Ophthalmology Vision Award (XOVA) for nonprofit sustainable eye health initiatives

Read More
Media Release / Sep 22, 2018

Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness

Read More
Media Release / Sep 22, 2018

New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD

Read More
Media Release / Sep 21, 2018

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

Read More
Media Release / Sep 21, 2018

Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe

Read More
Media Release / Sep 21, 2018

Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More